VBI Vaccines Inc (VBIV) Stock
VBIV is no longer traded. VBI Vaccines was delisted from the Nasdaq in August 2024.
Prices on this page are historical; the last trade was August 8, 2024 at $0.03.
VBI Vaccines stock price history
VBIV final trading statistics
- Final close
- $0.03
- Final trading day
- Aug 8, 2024
- Market cap at delisting
- $1.87M
- Shares outstanding
- 28.68M
- Final 52-week range
- $0.02 – $1.35
- Avg. volume (final 3 mo.)
- 8,451,169
- All-time high (split-adj.)
- $7231.68 · Mar 1998
- All-time low (split-adj.)
- $0.03 · Aug 2024
- Return since IPO
- -100.0%
- Beta
- 2.17
- Book value / share
- -$0.22
- Price / book
- -0.13
VBI Vaccines annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $8.68M | -$92.8M | -$9.29 |
| FY2022 | $1.08M | -$141.0M | -$0.43 |
| FY2021 | $631.0K | -$72.7M | -$0.27 |
| FY2020 | $1.06M | -$47.3M | -$0.21 |
| FY2019 | $2.22M | -$55.8M | -$0.45 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About VBI Vaccines Inc
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited, the National Research Council of Canada, and Coalition for Epidemic Preparedness Innovations. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
VBI Vaccines stock FAQ
What happened to VBI Vaccines stock?
VBI Vaccines stock was delisted from the Nasdaq. Its final close was $0.03 on August 8, 2024.
Is VBIV stock still trading?
No. VBIV was delisted from the Nasdaq in August 2024 and no longer trades on a U.S. exchange.
What was the last price of VBIV stock?
VBIV closed at $0.03 on its final trading day, August 8, 2024, for a market value of about $1.87M.
What were VBI Vaccines's revenue and earnings in its last full fiscal year?
VBI Vaccines reported revenue of $8.68M and net income of -$92.8M in fiscal 2023, its last full year as a public company.
When did VBI Vaccines go public?
VBI Vaccines Inc stock began trading on August 18, 1995.